{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T14:37:08Z","timestamp":1774535828045,"version":"3.50.1"},"reference-count":20,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T00:00:00Z","timestamp":1573689600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Thoracic Cancer"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>To compare the efficiency and toxicity of bevacizumab by intrapleural or intravenous infusion in the management of malignant pleural effusion in patients with non\u2010small\u2010cell lung cancer (NSCLC).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Sensitizing mutation negative NSCLC patients with malignant pleural effusion were randomized into two groups in 1:1 ratio. The pleural effusion was completely drained in 24\u2009hours; one group received intrapleural infusion and the second group received intravenous infusion of bevacizumab at a dose of 7.5 mg per kg bodyweight. The serum vascular endothelial growth factor (VEGF) was tested before and 72\u2009hours after injection of bevacizumab. Computerized tomography (CT) scan to evaluate pleural effusions was carried out at four weeks for each patient and their survival followed\u2010up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 67 patients were screened and 43 enrolled into the study. The response rate was 80% (16 of 20) in the intrapleural group and 66.7% (14 of 21) in the intravenous group. The median duration of response (DoR) of pleural effusion was 4.50\u2009months and 3.70\u2009months, respectively. The median serum VEGF level at 72\u2009hours decreased 67.25% in the intrapleural group and 57.19% in the intravenous group compared to baseline level (<jats:italic>P<\/jats:italic> =\u20090.276). The median serum VEGF level at 72\u2009hours decreased 52.02% compared to baseline level in patients\u2019 DoR less than three months and 68.33% in patients' DoR longer than three months, respectively (<jats:italic>P<\/jats:italic> =\u20090.014). The main side effects noted were mild to moderate hypertension, proteinuria and epistaxis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Bevacizumab intrapleural infusion had higher efficiency and higher safety than intravenous infusion in the management of malignant pleural effusion caused by NSCLC. The decreased level of serum VEGF at 72\u2009hours after bevacizumab treatment was closely related to the response rate and duration of the response of pleural effusion.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1759-7714.13238","type":"journal-article","created":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T00:18:32Z","timestamp":1573777112000},"page":"8-14","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["A randomized clinical study to compare intrapleural infusion with intravenous infusion of bevacizumab in the management of malignant pleural effusion in patients with non\u2010small\u2010cell lung cancer"],"prefix":"10.1111","volume":"11","author":[{"given":"Keke","family":"Nie","sequence":"first","affiliation":[{"name":"Department of Oncology Qingdao Cancer Hospital  Qingdao China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology Qingdao Cancer Hospital  Qingdao China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunhong","family":"You","sequence":"additional","affiliation":[{"name":"Department of Oncology Qingdao Cancer Hospital  Qingdao China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingjun","family":"Zhuang","sequence":"additional","affiliation":[{"name":"Department of Oncology PLA 971 Hospital  Qingdao China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9311-0000","authenticated-orcid":false,"given":"Chunling","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology Qingdao Central Hospital, the Affiliated Qingdao Central Hospital of Qingdao University  Qingdao China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2303-8784","authenticated-orcid":false,"given":"Youxin","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Oncology Qingdao Central Hospital, the Affiliated Qingdao Central Hospital of Qingdao University  Qingdao China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,11,14]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2014.457"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2014-205285"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.2001.280.6.C1375"},{"key":"e_1_2_7_5_1","first-page":"8019","article-title":"The role of VEGF in the diagnosis and treatment of malignant pleural effusion in patients with non\u2010small cell lung cancer ( Review )","volume":"17","author":"Chen YAO","year":"2018","journal-title":"Mol Med Rep"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-016-9618-0"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-012-2026-4"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0647"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-013-0315-7"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_2_7_11_1","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE).Version.2.0. Cancer Therapy Evaluation Program (CTEP)1999:183. [Cited 30 July 2019.] Available from URL:https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctc_indexterms_7-99.pdf."},{"key":"e_1_2_7_12_1","doi-asserted-by":"crossref","unstructured":"Management of malignant pleural effusions. American thoracic society.Am J Respir Crit Care Med2000;162(5):1987\u20132001.","DOI":"10.1164\/ajrccm.162.5.ats8-00"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2009-0109"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005392"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/00063198-200207000-00009"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.10.088"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S168391"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2018-0089"},{"key":"e_1_2_7_19_1","first-page":"1313","article-title":"Effective treatment for malignant pleural effusion and ascites with combined therapy of bevacizumab and cisplatin","volume":"1318","author":"Jiang L","year":"2016","journal-title":"Anticancer Res"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2016.01.006"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2019.02.042"}],"container-title":["Thoracic Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1759-7714.13238","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1759-7714.13238","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1759-7714.13238","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1759-7714.13238","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T02:57:59Z","timestamp":1694141879000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1759-7714.13238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,14]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["10.1111\/1759-7714.13238"],"URL":"https:\/\/doi.org\/10.1111\/1759-7714.13238","archive":["Portico"],"relation":{},"ISSN":["1759-7706","1759-7714"],"issn-type":[{"value":"1759-7706","type":"print"},{"value":"1759-7714","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,14]]},"assertion":[{"value":"2019-09-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}